Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Long-Term Investments: 2021-2023

Historic Long-Term Investments for Cullinan Therapeutics (CGEM) over the last 3 years, with Sep 2023 value amounting to $15.5 million.

  • Cullinan Therapeutics' Long-Term Investments fell 49.51% to $15.5 million in Q3 2023 from the same period last year, while for Sep 2023 it was $15.5 million, marking a year-over-year decrease of 49.51%. This contributed to the annual value of $80.9 million for FY2022, which is 42.39% down from last year.
  • Per Cullinan Therapeutics' latest filing, its Long-Term Investments stood at $15.5 million for Q3 2023, which was down 23.65% from $20.3 million recorded in Q2 2023.
  • In the past 5 years, Cullinan Therapeutics' Long-Term Investments ranged from a high of $140.4 million in Q4 2021 and a low of $15.5 million during Q3 2023.
  • Its 3-year average for Long-Term Investments is $74.2 million, with a median of $80.9 million in 2022.
  • Examining YoY changes over the last 5 years, Cullinan Therapeutics' Long-Term Investments showed a top increase of 197.09% in 2022 and a maximum decrease of 75.31% in 2022.
  • Cullinan Therapeutics' Long-Term Investments (Quarterly) stood at $140.4 million in 2021, then tumbled by 42.39% to $80.9 million in 2022, then slumped by 49.51% to $15.5 million in 2023.
  • Its last three reported values are $15.5 million in Q3 2023, $20.3 million for Q2 2023, and $112.8 million during Q1 2023.